垂体神经内分泌肿瘤术后复发的因素研究进展
Research Advances on Factors of Postoperative Recurrence of Pituitary Neuroendocrine Tumors
DOI: 10.12677/acm.2025.151268, PDF,    科研立项经费支持
作者: 高永超, 高永军*, 郭鹏彦, 乔鹏宇：昆明医科大学第二附属医院神经外科二病区，云南 昆明
关键词: 垂体神经内分泌肿瘤；各式垂体病损切除术；复发；因素；治疗；Pituitary Neuroendocrine Tumor； Pituitary Tumor Resection； Recurrence； Factors； Treatment
摘要: 垂体神经内分泌肿瘤是一种常见的颅内肿瘤，治疗方式主要为经蝶或经颅垂体瘤切除术，对于手术治疗的患者，术后是否复发会影响患者后续治疗方案以及生存预后，其中侵入鞍上或鞍旁区域的PitNET由于术中难以完全切除，术后12%~58%的患者会出现复发(本文复发定义采用2019年中国复发性垂体腺瘤诊治专家共识中的定义：垂体腺瘤切除术后已消失的症状体征再次出现；内分泌指标达到缓解标准后再次升高；影像学检查再次出现肿瘤生长)，即使瘤体被完全切除，10%~20%仍会在5~10年内复发。肿瘤的复发给患者带来经济和心理负担的同时降低了其生活质量。本文主要从影像学特征、病理学因素及其他因素三方面对术后PitNET复发的因素进行综述，以及对临床中PitNET的治疗方式提出个人建议，旨在为该病的临床治疗提供参考。
Abstract: Pituitary neuroendocrine tumor is a common intracranial tumor, and the treatment is mainly transsphenoidal or transcranial pituitary tumor resection. For patients undergoing surgical treatment, whether postoperative recurrence will affect the follow-up treatment plan and survival prognosis of the patients. Among them, the PitNET that invaded the suprasellar or parasellar area was difficult to be completely removed during surgery, and recurred in 12%~58% of patients after surgery. (In this paper, the definition of relapse was adopted in the expert consensus on diagnosis and treatment of recurrent pituitary adenoma in China in 2019: symptoms and signs that had disappeared after pituitary adenoma resection reappeared; Endocrine indexes increased again after reaching the remission standard; Tumor growth reappears on imaging.) And even if the tumor is completely removed, 10%~20% will recur within 5 to 10 years. The recurrence of tumors brings financial and psychological burden to patients and reduces their quality of life. This article mainly reviews the factors of postoperative recurrence of PitNET from three aspects: imaging features, pathological factors and other factors, and puts forward personal suggestions on the clinical treatment of PitNET, aiming at providing references for the clinical treatment of this disease.
文章引用：高永超, 高永军, 郭鹏彦, 乔鹏宇. 垂体神经内分泌肿瘤术后复发的因素研究进展[J]. 临床医学进展, 2025, 15(1): 2018-2025. https://doi.org/10.12677/acm.2025.151268

参考文献

[1] Bodhinayake, I., Ottenhausen, M., Mooney, M.A., Kesavabhotla, K., Christos, P., Schwarz, J.T., et al. (2014) Results and Risk Factors for Recurrence Following Endoscopic Endonasal Transsphenoidal Surgery for Pituitary Adenoma. Clinical Neurology and Neurosurgery, 119, 75-79. [Google Scholar] [CrossRef] [PubMed]
[2] Lu, L., Wan, X., Xu, Y., Chen, J., Shu, K. and Lei, T. (2022) Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions. Diagnostics, 12, Article 977. [Google Scholar] [CrossRef] [PubMed]
[3] O’Sullivan, E.P., Woods, C., Glynn, N., Behan, L.A., Crowley, R., O’Kelly, P., et al. (2009) The Natural History of Surgically Treated But Radiotherapy‐Naïve Nonfunctioning Pituitary Adenomas. Clinical Endocrinology, 71, 709-714. [Google Scholar] [CrossRef] [PubMed]
[4] Brochier, S., Galland, F., Kujas, M., Parker, F., Gaillard, S., Raftopoulos, C., et al. (2010) Factors Predicting Relapse of Nonfunctioning Pituitary Macroadenomas after Neurosurgery: A Study of 142 Patients. European Journal of Endocrinology, 163, 193-200. [Google Scholar] [CrossRef] [PubMed]
[5] Losa, M., Mortini, P., Barzaghi, R., Ribotto, P., Terreni, M.R., Marzoli, S.B., et al. (2008) Early Results of Surgery in Patients with Nonfunctioning Pituitary Adenoma and Analysis of the Risk of Tumor Recurrence. Journal of Neurosurgery, 108, 525-532. [Google Scholar] [CrossRef] [PubMed]
[6] Loeschner, D., Enciu, A., Kellner, G., Meyer, A., Wallaschofski, H., McLean, A.C.L., et al. (2023) Two-and Three-Dimensional Endoscopic Endonasal Surgery of Large and Giant Pituitary Adenomas—Outcome Analysis of a Series of 62 Patients from a Single Pituitary Center. Neurosurgical Review, 46, Article No. 150. [Google Scholar] [CrossRef] [PubMed]
[7] Estrada, J. (2001) The Complete Normalization of the Adrenocortical Function as the Criterion of Cure after Transsphenoidal Surgery for Cushing’s Disease. Journal of Clinical Endocrinology & Metabolism, 86, 5695-5699. [Google Scholar] [CrossRef] [PubMed]
[8] Lv, L., Yin, S., Zhou, P., Hu, Y., Chen, C., Ma, W., et al. (2018) Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up. World Neurosurgery, 118, e428-e435. [Google Scholar] [CrossRef] [PubMed]
[9] Juraschka, K., Khan, O.H., Godoy, B.L., Monsalves, E., Kilian, A., Krischek, B., et al. (2014) Endoscopic Endonasal Transsphenoidal Approach to Large and Giant Pituitary Adenomas: Institutional Experience and Predictors of Extent of Resection. Journal of Neurosurgery, 121, 75-83. [Google Scholar] [CrossRef] [PubMed]
[10] Ferreira, J.E.A., Mello, P.A.d., Magalhães, A.V.d., Botelho, C.H.A., Naves, L.A., Nosé, V., et al. (2005) Caracterização clínica e imunoistoquímica dos adenomas clinicamente não-funcionantes de hipófise: clinical features and immunohistochemistry. Arquivos de Neuro-Psiquiatria, 63, 1070-1078. [Google Scholar] [CrossRef] [PubMed]
[11] Raverot, G., Ilie, M.D., Lasolle, H., Amodru, V., Trouillas, J., Castinetti, F., et al. (2021) Aggressive Pituitary Tumours and Pituitary Carcinomas. Nature Reviews Endocrinology, 17, 671-684. [Google Scholar] [CrossRef] [PubMed]
[12] Li, C., Zhu, H., Zong, X., Wang, X., Gui, S., Zhao, P., et al. (2020) Experience of Trans-Nasal Endoscopic Surgery for Pituitary Tumors in a Single Center in China: Surgical Results in a Cohort of 2032 Patients, Operated between 2006 and 2018. Clinical Neurology and Neurosurgery, 197, Article ID: 106176. [Google Scholar] [CrossRef] [PubMed]
[13] Koutourousiou, M., Gardner, P.A., Fernandez-Miranda, J.C., Paluzzi, A., Wang, E.W. and Snyderman, C.H. (2013) Endoscopic Endonasal Surgery for Giant Pituitary Adenomas: Advantages and Limitations. Journal of Neurosurgery, 118, 621-631. [Google Scholar] [CrossRef] [PubMed]
[14] Elshazly, K., Kshettry, V.R., Farrell, C.J., Nyquist, G., Rosen, M. and Evans, J.J. (2018) Clinical Outcomes after Endoscopic Endonasal Resection of Giant Pituitary Adenomas. World Neurosurgery, 114, e447-e456. [Google Scholar] [CrossRef] [PubMed]
[15] Shou, X., Shen, M., Zhang, Q., Zhang, Y., He, W., Ma, Z., et al. (2016) Endoscopic Endonasal Pituitary Adenomas Surgery: The Surgical Experience of 178 Consecutive Patients and Learning Curve of Two Neurosurgeons. BMC Neurology, 16, Article No. 247. [Google Scholar] [CrossRef] [PubMed]
[16] Galm, B.P., Martinez-Salazar, E.L., Swearingen, B., Torriani, M., Klibanski, A., Bredella, M.A., et al. (2018) MRI Texture Analysis as a Predictor of Tumor Recurrence or Progression in Patients with Clinically Non-Functioning Pituitary Adenomas. European Journal of Endocrinology, 179, 191-198. [Google Scholar] [CrossRef] [PubMed]
[17] Asa, S.L., Mete, O., Perry, A. and Osamura, R.Y. (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocrine Pathology, 33, 6-26. [Google Scholar] [CrossRef] [PubMed]
[18] Villa, C., Baussart, B., Assié, G., Raverot, G. and Roncaroli, F. (2023) The World Health Organization Classifications of Pituitary Neuroendocrine Tumours: A Clinico-Pathological Appraisal. Endocrine-Related Cancer, 30, e230021. [Google Scholar] [CrossRef] [PubMed]
[19] Trouillas, J., Burman, P., McCormack, A., Petersenn, S., Popovic, V., Dekkers, O., et al. (2018) Aggressive Pituitary Tumours and Carcinomas: Two Sides of the Same Coin? European Journal of Endocrinology, 178, C7-C9. [Google Scholar] [CrossRef] [PubMed]
[20] Trouillas, J., Jaffrain-Rea, M., Vasiljevic, A., Dekkers, O., Popovic, V., Wierinckx, A., et al. (2020) Are Aggressive Pituitary Tumors and Carcinomas Two Sides of the Same Coin? Pathologists Reply to Clinician’s Questions. Reviews in Endocrine and Metabolic Disorders, 21, 243-251. [Google Scholar] [CrossRef] [PubMed]
[21] Scheithauer, B.W., Jaap, A.J., Horvath, E., Kovacs, K., Lloyd, R.V., Meyer, F.B., et al. (2000) Clinically Silent Corticotroph Tumors of the Pituitary Gland. Neurosurgery, 47, 723-730. [Google Scholar] [CrossRef] 
[22] Sumislawski, P., Huckhagel, T., Krajewski, K.L., Aberle, J., Saeger, W., Flitsch, J., et al. (2023) Cystic versus Non-Cystic Silent Corticotrophic Adenomas: Clinical and Histological Analysis of 62 Cases after Microscopic Transsphenoidal Surgery—A Retrospective, Single-Center Study. Scientific Reports, 13, Article No. 2468. [Google Scholar] [CrossRef] [PubMed]
[23] Braun, L.T., Rubinstein, G., Zopp, S., Vogel, F., Schmid-Tannwald, C., Escudero, M.P., et al. (2020) Recurrence after Pituitary Surgery in Adult Cushing’s Disease: A Systematic Review on Diagnosis and Treatment. Endocrine, 70, 218-231. [Google Scholar] [CrossRef] [PubMed]
[24] Liu, Y., Liu, X., Hong, X., Liu, P., Bao, X., Yao, Y., et al. (2019) Prediction of Recurrence after Transsphenoidal Surgery for Cushing’s Disease: The Use of Machine Learning Algorithms. Neuroendocrinology, 108, 201-210. [Google Scholar] [CrossRef] [PubMed]
[25] Mayberg, M., Reintjes, S., Patel, A., Moloney, K., Mercado, J., Carlson, A., et al. (2018) Dynamics of Postoperative Serum Cortisol after Transsphenoidal Surgery for Cushing’s Disease: Implications for Immediate Reoperation and Remission. Journal of Neurosurgery, 129, 1268-1277. [Google Scholar] [CrossRef] [PubMed]
[26] Roelfsema, F., Biermasz, N.R. and Pereira, A.M. (2011) Clinical Factors Involved in the Recurrence of Pituitary Adenomas after Surgical Remission: A Structured Review and Meta-analysis. Pituitary, 15, 71-83. [Google Scholar] [CrossRef] [PubMed]
[27] Forsyth, P.A., Wong, H., Laing, T.D., Rewcastle, N.B., Morris, D.G., Muzik, H., et al. (1999) Gelatinase-A (MMP-2), Gelatinase-B (MMP-9) and Membrane Type Matrix Metalloproteinase-1 (MT1-MMP) Are Involved in Different Aspects of the Pathophysiology of Malignant Gliomas. British Journal of Cancer, 79, 1828-1835. [Google Scholar] [CrossRef] [PubMed]
[28] Guo, H., Sun, Z., Wei, J., Xiang, Y., Qiu, L., Guo, L., et al. (2019) Expressions of Matrix Metalloproteinases-9 and Tissue Inhibitor of Metalloproteinase-1 in Pituitary Adenomas and Their Relationships with Prognosis. Cancer Biotherapy and Radiopharmaceuticals, 34, 1-6. [Google Scholar] [CrossRef] [PubMed]
[29] Liu, X., Feng, M., Zhang, Y., Dai, C., Sun, B., Bao, X., et al. (2018) Expression of Matrix Metalloproteinase-9, Pituitary Tumor Transforming Gene, High Mobility Group a 2, and Ki-67 in Adrenocorticotropic Hormone-Secreting Pituitary Tumors and Their Association with Tumor Recurrence. World Neurosurgery, 113, e213-e221. [Google Scholar] [CrossRef] [PubMed]
[30] Xiong, Z., Li, X. and Yang, Q. (2019) PTTG Has a Dual Role of Promotion-Inhibition in the Development of Pituitary Adenomas. Protein & Peptide Letters, 26, 800-818. [Google Scholar] [CrossRef] [PubMed]
[31] Tfelt-Hansen, J., Kanuparthi, D. and Chattopadhyay, N. (2006) The Emerging Role of Pituitary Tumor Transforming Gene in Tumorigenesis. Clinical Medicine & Research, 4, 130-137. [Google Scholar] [CrossRef] [PubMed]
[32] Gruppetta, M., Formosa, R., Falzon, S., Ariff Scicluna, S., Falzon, E., Degeatano, J., et al. (2017) Expression of Cell Cycle Regulators and Biomarkers of Proliferation and Regrowth in Human Pituitary Adenomas. Pituitary, 20, 358-371. [Google Scholar] [CrossRef] [PubMed]
[33] Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. [Google Scholar] [CrossRef] [PubMed]
[34] Stirling, E.R., Bronson, S.M., Mackert, J.D., Cook, K.L., Triozzi, P.L. and Soto-Pantoja, D.R. (2022) Metabolic Implications of Immune Checkpoint Proteins in Cancer. Cells, 11, Article 179. [Google Scholar] [CrossRef] [PubMed]
[35] Xi, Z., Jones, P.S., Mikamoto, M., Jiang, X., Faje, A.T., Nie, C., et al. (2021) The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas. Frontiers in Endocrinology, 12, Article 726448. [Google Scholar] [CrossRef] [PubMed]
[36] Uraki, S., Ariyasu, H., Doi, A., Takeshima, K., Morita, S., Inaba, H., et al. (2020) MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes. International Journal of Molecular Sciences, 21, Article 2831. [Google Scholar] [CrossRef] [PubMed]
[37] Zhou, W., Zhang, C., Zhang, D., Peng, J., Ma, S., Wang, X., et al. (2020) Comprehensive Analysis of the Immunological Landscape of Pituitary Adenomas: Implications of Immunotherapy for Pituitary Adenomas. Journal of Neuro-Oncology, 149, 473-487. [Google Scholar] [CrossRef] [PubMed]
[38] Liu, X., Feng, M., Dai, C., Bao, X., Deng, K., Yao, Y., et al. (2019) Expression of EGFR in Pituitary Corticotroph Adenomas and Its Relationship with Tumor Behavior. Frontiers in Endocrinology, 10, Article 785. [Google Scholar] [CrossRef] [PubMed]
[39] Rai, A., Das, L., Mukherjee, K.K., Dhandapani, S., Tripathi, M., Ahuja, C.K., et al. (2021) Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas. Frontiers in Endocrinology, 12, Article 70811. [Google Scholar] [CrossRef] [PubMed]
[40] Lyu, W., Fei, X., Chen, C. and Tang, Y. (2021) Nomogram Predictive Model of Post-Operative Recurrence in Non-Functioning Pituitary Adenoma. Gland Surgery, 10, 807-815. [Google Scholar] [CrossRef] [PubMed]
[41] Trott, G., Ongaratti, B.R., de Oliveira Silva, C.B., Abech, G.D., Haag, T., Rech, C.G.S.L., et al. (2019) PTTG Overexpression in Non-Functioning Pituitary Adenomas: Correlation with Invasiveness, Female Gender and Younger Age. Annals of Diagnostic Pathology, 41, 83-89. [Google Scholar] [CrossRef] [PubMed]
[42] Watts, A.K., Easwaran, A., McNeill, P., Wang, Y.Y., Inder, W.J. and Caputo, C. (2017) Younger Age Is a Risk Factor for Regrowth and Recurrence of Nonfunctioning Pituitary Macroadenomas: Results from a Single Australian Centre. Clinical Endocrinology, 87, 264-271. [Google Scholar] [CrossRef] [PubMed]
[43] Chen, Y., Cai, F., Cao, J., Gao, F., Lv, Y., Tang, Y., et al. (2021) Analysis of Related Factors of Tumor Recurrence or Progression after Transnasal Sphenoidal Surgical Treatment of Large and Giant Pituitary Adenomas and Establish a Nomogram to Predict Tumor Prognosis. Frontiers in Endocrinology, 12, Article 793337. [Google Scholar] [CrossRef] [PubMed]
[44] van Imhoff, L.C.R., Kranenburg, G.G.J., Macco, S., Nijman, N.L., van Overbeeke, E.J., Wegner, I., et al. (2015) Prognostic Value of Continued Smoking on Survival and Recurrence Rates in Patients with Head and Neck Cancer: A Systematic Review. Head & Neck, 38, E2214-E2220. [Google Scholar] [CrossRef] [PubMed]
[45] Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F. and Straif, K. (2016) Body Fatness and Cancer—Viewpoint of the IARC Working Group. New England Journal of Medicine, 375, 794-798. [Google Scholar] [CrossRef] [PubMed]
[46] Renehan, A.G., Tyson, M., Egger, M., Heller, R.F. and Zwahlen, M. (2008) Body-mass Index and Incidence of Cancer: A Systematic Review and Meta-Analysis of Prospective Observational Studies. The Lancet, 371, 569-578. [Google Scholar] [CrossRef] [PubMed]
[47] Wiedmann, M.K.H., Brunborg, C., Di Ieva, A., Lindemann, K., Johannesen, T.B., Vatten, L., et al. (2017) Overweight, Obesity and Height as Risk Factors for Meningioma, Glioma, Pituitary Adenoma and Nerve Sheath Tumor: A Large Population-Based Prospective Cohort Study. Acta Oncologica, 56, 1302-1309. [Google Scholar] [CrossRef] [PubMed]
[48] Chang, E.F., Zada, G., Kim, S., Lamborn, K.R., Quinones-Hinojosa, A., Tyrrell, J.B., et al. (2008) Long-term Recurrence and Mortality after Surgery and Adjuvant Radiotherapy for Nonfunctional Pituitary Adenomas. Journal of Neurosurgery, 108, 736-745. [Google Scholar] [CrossRef] [PubMed]
[49] Hussein, Z., Grieve, J., Dorward, N., Miszkiel, K., Kosmin, M., Fersht, N., et al. (2023) Non-functioning Pituitary Macroadenoma Following Surgery: Long-Term Outcomes and Development of an Optimal Follow-Up Strategy. Frontiers in Surgery, 10, Article 1129387. [Google Scholar] [CrossRef] [PubMed]
[50] Charleux, T., Vendrely, V., Huchet, A., Trouette, R., Ferrière, A., Tabarin, A., et al. (2022) Management after Initial Surgery of Nonfunctioning Pituitary Adenoma: Surveillance, Radiotherapy or Surgery? Radiation Oncology, 17, Article No. 165. [Google Scholar] [CrossRef] [PubMed]

为你推荐